FDA launched a Rare Disease Framework Initiative with comments open to Dec 11. Here's what it builds on, what isn't changing, and what sponsors should do.
Where nitrosamine and NDSRI control stands after FDA's August 2025 progress report change: CPCA limits, EMA Article 5(3) Q&A, mitigation and submission pathways.